These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12722392)

  • 1. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
    Kobierski J; Majdak E; Mielcarek P; Emerich J
    Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premedication strategy for weekly paclitaxel.
    Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
    Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose dexamethasone paclitaxel premedication.
    Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
    Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
    de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
    Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
    Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis for paclitaxel hypersensitivity reactions.
    Kintzel PE
    Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
    Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
    Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
    Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel premedication regimens.
    Boehm DK; Maksymiuk AW
    J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
    Jeerakornpassawat D; Suprasert P
    Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
    Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
    Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
    Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
    Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
    Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
    Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
    Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
    Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity reaction to paclitaxel: nursing interventions.
    Myers JS
    Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.